ストックスクリーナーアプリを入手
38.93
1.09%
0.42
アフターアワーズ：
39.67
0.74
+1.90%
Moonlake Immunotherapeutics (MLTX) 最新ニュース
Wolfe Research lifts Moonlake stock to Outperform By Investing.com - Investing.com Canada
Wolfe Research lifts Moonlake stock to Outperform - Investing.com Australia
Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) with a Bullish Outlook | MLTX Stock News - GuruFocus
Wolfe upgrades MoonLake Immunotherapeutics ahead of sonelokimab data - TipRanks
Wolfe Research Upgrades MoonLake (MLTX) to Outperform with New P - GuruFocus
MoonLake Immunotherapeutics Stock Gains Momentum - TipRanks
Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
Wolfe Research Upgrades MoonLake Immunotherapeutics to Outperform From Peer Perform - marketscreener.com
Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX), Sets $61 Target | MLTX Stock News - GuruFocus
Ameriprise Financial Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Wedbush Issues Positive Forecast for MLTX Earnings - Defense World
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet - MSN
RBC Capital Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
MoonLake Immunotherapeutics: Buy Rating Driven by Strategic Developments and Promising Clinical Programs - TipRanks
Dimensional Fund Advisors LP Purchases Shares of 64,384 MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics: Strong Financials and Promising Pipeline Drive Buy Rating - TipRanks
Needham Reiterates Buy Rating for MoonLake (MLTX) with Price Tar - GuruFocus
MoonLake Immunotherapeutics: Strong Financial Position and Promising Data Releases Justify Buy Rating - TipRanks
Decoding MoonLake Immunotherapeutics (MLTX): A Strategic SWOT In - GuruFocus
Promising Growth Potential and Financial Strength Drive Buy Rating for MoonLake Immunotherapeutics - TipRanks
MoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy Rating - TipRanks
MoonLake Immunotherapeutics Q1 Loss Widens - marketscreener.com
MoonLake Immunotherapeutics (MLTX) Strengthens Financial Positio - GuruFocus
MoonLake Immunotherapeutics reports results for the quarter ended March 31Earnings Summary - TradingView
MoonLake Immunotherapeutics reports Q1 EPS (63c), consensus (74c) - TipRanks
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire
Hot Picks in biotechnology - BNN Bloomberg
In the Green: MoonLake Immunotherapeutics (MLTX) Closes at 37.60, Up/Down -4.24 from Previous Day - DWinneX
MoonLake Immunotherapeutics’ SWOT analysis: biopharma stock faces challenges and opportunities - Investing.com Canada
Mariner LLC Makes New Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
The biggest biotech funding rounds in April 2025 - Labiotech.eu
MoonLake Immunotherapeutics’ (MLTX) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
(MLTX) Investment Analysis - news.stocktradersdaily.com
MoonLake Immunotherapeutics: Promising Clinical Updates and Market Potential Support Buy Rating - TipRanks
RBC Capital Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
MoonLake Immunotherapeutics (MLTX) receives an Outperform rating from RBC Capital Mkts - knoxdaily.com
MoonLake Immunotherapeutics Shares Surge Ahead of Key Event - TipRanks
MoonLake Immunotherapeutics price target raised to $85 from $81 at BTIG - TipRanks
MoonLake Immunotherapeutics: Promising Developments and Financial Strength Justify Buy Rating - TipRanks
BTIG Boosts Price Target for MoonLake Immunotherapeutics (MLTX) to $85 | MLTX Stock News - GuruFocus
MoonLake Immunotherapeutics: Promising Developments and Strategic Positioning Justify Buy Rating - TipRanks
MoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy Rating - TipRanks
Ratio Analysis: Unpacking MoonLake Immunotherapeutics (MLTX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
MoonLake Immunotherapeutics Hosts Capital Markets Day - TipRanks
Geode Capital Management LLC Purchases 540 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
LPL Financial LLC Buys 1,332 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - American Banking and Market News
LPL Financial LLC Purchases 1,332 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 - GlobeNewswire
Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Rating of “Buy” from Brokerages - Defense World
17.27%
1.06%
大文字化:
|
ボリューム (24 時間):